Michel Thérien

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

Jacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 467 citations · Full text

Molecular Pharmacology, Pharmaceutical Chemistry, Biochemistry +11

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 426 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Active Cyclooxygenase-2 Inhibitor +10

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

Denis Riendeau, M. David Percival, S. Boyce et al. · British Journal of Pharmacology · 1997 · 326 citations · Full text

Pge2 Production, Chemoprevention Strategy, Immunology +16

Difluoroethylamines as an amide isostere in inhibitors of cathepsin K

Élise Isabel, Christophe Mellon, Michael J. Boyd et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 111 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Science +10

Regiocontrolled opening of cyclic ethers using dimethylboron bromide

Yvan Guindon, Michel Thérien, Yves Girard et al. · The Journal of Organic Chemistry · 1987 · 109 citations

Alkene Metathesis, Dimethylboron Bromide, Information +8